N-Benzyl Benzamide Derivatives as Selective Sub-Nanomolar Butyrylcholinesterase Inhibitors for Possible Treatment in Advanced Alzheimer’s Disease
Chenxi Du, Lei Wang, Qianwen Guan, Hongyu Yang, Tingkai Chen, Yijun Liu, Qihang Li, Weiping Lyu 等 18 位
China Pharmaceutical University Jiangsu Food and Pharmaceutical Science College Yantai University Nanjing University of Chinese Medicine
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Herein, we report a series of selective sub-nanomolar inhibitors against butyrylcholinesterase (BChE). These compounds, bearing a novel N -benzyl benzamide scaffold, inhibited BChE with IC 50 from picomolar to nanomolar. The inhibitory activity was confirmed by the surface plasmon resonance assay, showing a sub-nanomolar K D value, which revealed that the compounds exert the inhibitory effect through directly binding to BChE. Several compounds showed neuroprotective effects verified by the oxidative damage model. Furthermore, the safety of S11-1014 and S11-1033 was demonstrated by the in vivo acute toxicity test. In the behavior study, 0.5 mg/kg S11-1014 or S11-1033 exhibited a marked therapeutic effect, which was almost equal to the treatment with 1 mg/kg rivastigmine, against the cognitive impairment induced by Aβ 1–42 . The pharmacokinetics studies characterized the metabolic stability of S11-1014 . Thus, N -benzyl benzamide inhibitors are promising compounds with drug-like properties for improving cognitive dysfunction, providing a potential strategy for the treatment of Alzheimer’s disease.
逐年被引趋势
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Cholinesterase and Neurodegenerative Diseases
Alzheimer's disease research and treatments · Enzyme function and inhibition